Involvement of the DNA Mismatch Repair System in Cisplatin Sensitivity of Testicular Germ Cell Tumours

Overview

Journal Cell Oncol (Dordr)

Publisher Springer

Date 2017 May 25

PMID 28536927

Citations 18

Authors

Christiane Rudolph

Cecilie Melau

John E Nielsen

Kristina Vile Jensen

Dekang Liu

Javier Pena-Diaz

Ewa Rajpert-De Meyts

Lene Juel Rasmussen

Anne Jorgensen

Affiliations

Soon will be listed here.

Abstract

Background: Testicular germ cell tumours (TGCT) are highly sensitive to cisplatin-based chemotherapy, but patients with tumours containing differentiated teratoma components are less responsive to this treatment. The cisplatin sensitivity in TGCT has previously been linked to the embryonic phenotype in the majority of tumours, although the underlying mechanism largely remains to be elucidated. The aim of this study was to investigate the role of the DNA mismatch repair (MMR) system in the cisplatin sensitivity of TGCT.

Methods: The expression pattern of key MMR proteins, including MSH2, MSH6, MLH1 and PMS2, were investigated during testis development and in the pathogenesis of TGCT, including germ cell neoplasia in situ (GCNIS). The TGCT-derived cell line NTera2 was differentiated using retinoic acid (10 μM, 6 days) after which MMR protein expression and activity, as well as cisplatin sensitivity, were investigated in both undifferentiated and differentiated cells. Finally, the expression of MSH2 was knocked down by siRNA in NTera2 cells after which the effect on cisplatin sensitivity was examined.

Results: MMR proteins were expressed in proliferating cells in the testes, while in malignant germ cells MMR protein expression was found to coincide with the expression of the pluripotency factor OCT4, with no or low expression in the more differentiated yolk sac tumours, choriocarcinomas and teratomas. In differentiated NTera2 cells we found a significantly (p < 0.05) lower expression of the MMR and pluripotency factors, as well as a reduced MMR activity and cisplatin sensitivity, compared to undifferentiated NTera2 cells. Also, we found that partial knockdown of MSH2 expression in undifferentiated NTera2 cells resulted in a significantly (p < 0.001) reduced cisplatin sensitivity.

Conclusion: This study reports, for the first time, expression of the MMR system in fetal gonocytes, from which GCNIS cells are derived. Our findings in primary TGCT specimens and TGCT-derived cells suggest that a reduced sensitivity to cisplatin in differentiated TGCT components could result from a reduced expression of MMR proteins, in particular MSH2 and MLH1, which are involved in the recognition of cisplatin adducts and in activation of the DNA damage response pathway to initiate apoptosis.

Citing Articles

Identification of a prognostic gene signature in patients with cisplatin resistant squamous cell lung cancer.

Mu Y, Dong Y, Zheng M, Barr M, Roviello G, Hu Z J Thorac Dis. 2024; 16(7):4567-4583.

PMID: 39144297 PMC: 11320240. DOI: 10.21037/jtd-24-827.

Biomarkers for Salvage Therapy in Testicular Germ Cell Tumors.

Urbini M, Bleve S, Schepisi G, Menna C, Gurioli G, Gianni C Int J Mol Sci. 2023; 24(23).

PMID: 38069192 PMC: 10706346. DOI: 10.3390/ijms242316872.

Pathogenic Insights into DNA Mismatch Repair (MMR) Genes-Proteins and Microsatellite Instability: Focus on Adrenocortical Carcinoma and Beyond.

Carsote M, Turturea I, Turturea M, Valea A, Nistor C, Gheorghisan-Galateanu A Diagnostics (Basel). 2023; 13(11).

PMID: 37296718 PMC: 10252762. DOI: 10.3390/diagnostics13111867.

Immune checkpoint inhibitors and Chimeric Antigen Receptor (CAR)-T cell therapy: Potential treatment options against Testicular Germ Cell Tumors.

Schepisi G, Gianni C, Cursano M, Galla V, Menna C, Casadei C Front Immunol. 2023; 14:1118610.

PMID: 36860862 PMC: 9968831. DOI: 10.3389/fimmu.2023.1118610.

Glutathione-sensitive nanoparticles enhance the combined therapeutic effect of checkpoint kinase 1 inhibitor and cisplatin in prostate cancer.

Peng S, Zhang X, Huang H, Cheng B, Xiong Z, Du T APL Bioeng. 2022; 6(4):046106.

PMID: 36440378 PMC: 9686925. DOI: 10.1063/5.0126095.

References

Andrews P . Retinoic acid induces neuronal differentiation of a cloned human embryonal carcinoma cell line in vitro. Dev Biol. 1984; 103(2):285-93. DOI: 10.1016/0012-1606(84)90316-6. View

Hoei-Hansen C, Nielsen J, Almstrup K, Sonne S, Graem N, Skakkebaek N . Transcription factor AP-2gamma is a developmentally regulated marker of testicular carcinoma in situ and germ cell tumors. Clin Cancer Res. 2004; 10(24):8521-30. DOI: 10.1158/1078-0432.CCR-04-1285. View

Mayer F, Stoop H, Scheffer G, Scheper R, Oosterhuis J, Looijenga L . Molecular determinants of treatment response in human germ cell tumors. Clin Cancer Res. 2003; 9(2):767-73. View

Haraldsdottir S, Hampel H, Tomsic J, Frankel W, Pearlman R, de la Chapelle A . Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations. Gastroenterology. 2014; 147(6):1308-1316.e1. PMC: 4294551. DOI: 10.1053/j.gastro.2014.08.041. View

Salsbury Jr F, Clodfelter J, Gentry M, Hollis T, Scarpinato K . The molecular mechanism of DNA damage recognition by MutS homologs and its consequences for cell death response. Nucleic Acids Res. 2006; 34(8):2173-85. PMC: 1450329. DOI: 10.1093/nar/gkl238. View

De Jong J, Stoop H, Dohle G, Bangma C, Kliffen M, van Esser J . Diagnostic value of OCT3/4 for pre-invasive and invasive testicular germ cell tumours. J Pathol. 2005; 206(2):242-9. DOI: 10.1002/path.1766. View

Baker S, Plug A, Prolla T, Bronner C, Harris A, Yao X . Involvement of mouse Mlh1 in DNA mismatch repair and meiotic crossing over. Nat Genet. 1996; 13(3):336-42. DOI: 10.1038/ng0796-336. View

Almstrup K, Nielsen J, Mlynarska O, JANSEN M, Jorgensen A, Skakkebaek N . Carcinoma in situ testis displays permissive chromatin modifications similar to immature foetal germ cells. Br J Cancer. 2010; 103(8):1269-76. PMC: 2967056. DOI: 10.1038/sj.bjc.6605880. View

Jacobsen C, Honecker F . Cisplatin resistance in germ cell tumours: models and mechanisms. Andrology. 2014; 3(1):111-21. DOI: 10.1111/andr.299. View

10.

Higby D, WALLACE Jr H, Albert D, HOLLAND J . Diaminodichloroplatinum: a phase I study showing responses in testicular and other tumors. Cancer. 1974; 33(5):1219-5. DOI: 10.1002/1097-0142(197405)33:5<1219::aid-cncr2820330505>3.0.co;2-u. View

11.

Svingen T, Jorgensen A, Rajpert-De Meyts E . Validation of endogenous normalizing genes for expression analyses in adult human testis and germ cell neoplasms. Mol Hum Reprod. 2014; 20(8):709-18. DOI: 10.1093/molehr/gau030. View

12.

Verhoeven R, Gondos A, Janssen-Heijnen M, Saum K, Brewster D, Holleczek B . Testicular cancer in Europe and the USA: survival still rising among older patients. Ann Oncol. 2012; 24(2):508-513. DOI: 10.1093/annonc/mds460. View

13.

Velasco A, Riquelme E, Schultz M, Wistuba I, Villarroel L, Pizarro J . Mismatch repair gene expression and genetic instability in testicular germ cell tumor. Cancer Biol Ther. 2004; 3(10):977-82. DOI: 10.4161/cbt.3.10.1135. View

14.

Velasco A, Riquelme E, Schultz M, Wistuba I, Villarroel L, Koh M . Microsatellite instability and loss of heterozygosity have distinct prognostic value for testicular germ cell tumor recurrence. Cancer Biol Ther. 2004; 3(11):1152-8. DOI: 10.4161/cbt.3.11.1218. View

15.

Mello J, Acharya S, Fishel R, Essigmann J . The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin. Chem Biol. 1996; 3(7):579-89. DOI: 10.1016/s1074-5521(96)90149-0. View

16.

Trabert B, Chen J, Devesa S, Bray F, McGlynn K . International patterns and trends in testicular cancer incidence, overall and by histologic subtype, 1973-2007. Andrology. 2014; 3(1):4-12. PMC: 4410839. DOI: 10.1111/andr.293. View

17.

Marra G, DAtri S, Yan H, Perrera C, Cannavo E, Vogelstein B . Phenotypic analysis of hMSH2 mutations in mouse cells carrying human chromosomes. Cancer Res. 2001; 61(21):7719-21. View

18.

Jorgensen A, Blomberg Jensen M, Nielsen J, Juul A, Rajpert-De Meyts E . Influence of vitamin D on cisplatin sensitivity in testicular germ cell cancer-derived cell lines and in a NTera2 xenograft model. J Steroid Biochem Mol Biol. 2012; 136:238-46. DOI: 10.1016/j.jsbmb.2012.10.008. View

19.

Young J, Wakitani S, Loveland K . TGF-β superfamily signaling in testis formation and early male germline development. Semin Cell Dev Biol. 2015; 45:94-103. DOI: 10.1016/j.semcdb.2015.10.029. View

20.

Topping R, Wilkinson J, Scarpinato K . Mismatch repair protein deficiency compromises cisplatin-induced apoptotic signaling. J Biol Chem. 2009; 284(21):14029-39. PMC: 2682851. DOI: 10.1074/jbc.M809303200. View